medic suppli devic
converg valuat upgrad buy
downgrad neutral
messag head two stori much
common compani diversifi mega-cap healthcar asset set undergo
leadership chang spring yet fundament perspect believ
compani head differ direct growth pois moder
impress multi-year run cusp best period pipeline-driven
growth acceler sinc immedi covidien merger five year ago
expect converg fundament pictur result narrow valuat gap
two stock result upgrad buy neutral
pt downgrad neutral buy remov pt
expect year much-tout pipelin begin show
compani number near-term catalyst includ fda approv micra av
leadless pacemak insulin pump long-term project
like hugo robot surgeri platform intrepid tmvr symplic system could
begin move needl beyond expect face increas
competit area like tavr implant cardiac monitor spinal cord stimul
sacral nerv modul new product launch segment mitig
potenti share loss take piec account see clear pathway
sustain top line growth beyond acceler
organ growth also expect activ front geoff
martha leadership reinvigor piec compani overal growth strategi
believ becom much conserv recent
visibl improv growth trajectori increas expect medtron
valuat discount rel rest large-cap med-tech group narrow
share current trade ep estim discount large-
cap med-tech averag gap still
much larger discount trade
last time compani strung togeth quarter top-lin growth
believ similar dynam could play move top-
line momentum build new price target base multipl
forward ntm ep estim discount current large-cap med-tech
group averag given signific upsid potenti target current level
upgrad share neutral buy
meanwhil back-to-back year strong top-lin momentum see abbott
growth moder stori go forward compani sheer size would make
maintain recent pace challeng circumst despit abbott
diversif truth recent growth acceler driven primarili
singl product libr although bullish broader cgm market
libr growth potenti expect libr contribut abbott
overal growth rate fade pace cgm penetr slow compani
pipelin includ promis growth driver pale comparison libr scale
explos ramp result like moder growth abbott whole
model call gradual deceler
page analyst certif import disclosur
see less opportun abbott drive leverag incom statement
go forward well compani grown earn compound-annual-growth-rate
driven strong top line momentum ebita margin expans back st jude
deal synergi fall interest expens manag delev post st jude
aler reduct tax rate expect abbott grow earn
compound-annual-growth-rate level roughli in-lin large-cap med-tech averag
slower top line reduc oper leverag opportun crimp earn power
balanc sheet notabl bright spot provid new ceo robert ford ampl
flexibl continu priorit de-lever buy back stock reengag
front year hiatu financi leverag much howev could
requir tradeoff near-term ep invest futur growth
top- bottom-lin growth rate moder see abbott prime
candid multipl compress stock current trade ep
estim premium large-cap med-tech averag roll
sector multipl forward assum abbott premium evapor investor
price slow growth would impli stock price gain current level
better opportun elsewher coverag downgrad share
buy neutral
page analyst certif import disclosur
upgrad buy downgrad neutral
head abbott two stori much common
compani boast diversifi busi model top line made
bellweth medic devic sector undergo leadership transit
next month mile white set step march
tenur ceo abbott omar ishrak april year
helm men transit execut chairman role
yet much common see abbott head
differ direct fundament perspect cusp
believ sustain pipeline-driven growth acceler abbott top-lin
momentum moder sever year strong gain expect shift result
narrow perform gap two compani one lead
converg valuat assign stock result
upgrad buy neutral establish price target
base multipl forward ntm ep estim downgrad
neutral buy remov price target
talk what chang let discuss weve histor
caution first time weve recommend stock nearli year
guggenheim driven belief compani lack necessari growth
driver sustain top line momentum par broader large-cap med-tech group
result deserv trade meaning discount peer thesi
larg play organ revenu growth averag sinc
share under-perform large-cap index past four year trail
 three four period meanwhil prior bullish abbott
base view street underestim posit impact st jude
acquisit would compani medic devic busi robust st
jude pipelin combin intern growth driver like libr alin would drive
acceler top line growth strong margin leverag abbott organ revenu growth
averag past two year
compani ebita margin sinc result three straight
year strong stock perform share stock trade ntm
ep vs time initi
factset guggenheim secur llc estim
project next year howev expect fundament
abbott converg side see pipeline-driven
revenu acceler solid progress margin lead top bottom
line growth meanwhil view abbott growth moder stori
model call organ revenu growth deceler
earn gain slow
page analyst certif import disclosur
manag team tout robust pipelin
time expect year impact new product flow begin
show compani number see upcom fda approv micra
av leadless pacemak particular meaning catalyst micra alreadi
product today despit narrow indic limit applic
pacemak patient product becom domin within singl
chamber pacer segment rise becom frequent use devic market
domest help gain roughli point unit share point
revenu share sinc launch av approv anticip
end april expand micra address market pacemak
patient driven expand label estim micra sale ramp
page analyst certif import disclosur
elsewher launch could revit struggl diabet
franchis despit insulin pump market leader compani
notic left behind amid broader acceler diabet technolog adopt
past two year held back share loss pump inferior cgm product offer
issu like compound near-term pathway
program current offer out-of-warranti custom new mdi convert
allow patient receiv today automat upgrad
addit charg pump approv defer revenu
custom enrol pathway program depress near-term result provid
increment boost post approv expect remain rel
laggard pump market due cgm product gap estim compani
diabet busi could still grow low double-digit clip low single-
digit result revenu deferr dynam improv underli
momentum driven launch
long-term pipelin includ number import program
begin move needl beyond includ
compani hugo robot surgeri platform formal unveil investor event
septemb see takeaway intrepid transcathet mitral valv replac
system pivot trial underway sever enhanc deep brain stimul
franchis potenti fda approv symplic renal denerv system
result symplic off-m pivot trial schedul present
march expect data posit base pre-pivot studi
conduct last year overcom challeng led
fail trial open believ could eventu multi-
billion-dollar market treatment drug-resist hypertens elsewher although
face increment competit tavr implant cardiac
monitor spinal cord stimul sacral nerv modul market new product
launch segment mitig potenti share loss take
piec togeth see clear pathway sustain top line growth
beyond acceler organ growth also expect activ
 front geoff martha leadership one area believ
compani conserv recent pull trigger two deal
past three year mazor robot epix contrast boston
scientif done acquisit time period despit
much less balanc sheet flexibl prior becom group presid
medtron restor therapi segment mr martha head strategi
busi develop seat led covidien merger
join oversaw global busi develop
see mr martha uniqu well-suit reinvigor portion
visibl improv growth trajectori increas expect medtron
valuat discount rel rest large-cap med-tech group narrow
share current trade ep estim discount large-
cap med-tech averag gap still
much larger discount trade
last time compani strung togeth quarter top-lin growth
page analyst certif import disclosur
believ similar dynam could play move medtron
top-lin momentum build new price target base
multipl forward ntm ep estim valuat repres
discount current large-cap med-tech group averag given signific upsid
potenti target current level upgrad share
neutral buy
figur organ revenu growth vs ntm price-to-earnings rel lc med-tech
compani report guggenheim secur llc estim
meanwhil back-to-back year top-lin gain see abbott
growth moder stori go forward earli jump bandwagon
back base belief st jude acquisit would posit
impact compani medic devic segment street appreci
immedi aftermath deal stock becom consensu long
time sinc analyst buy-rat today vs stock
reward premium multipl match compani impress
fundament perform share trade ep estim today
expect abbott continu deliv strong result year ahead see
valuat full model call top- bottom-lin growth
moder next year believ stock risk multipl compress
expect abbott revenu growth slow one thing compani size
simpli make challeng maintain recent pace model call
sale approach abbott must gener increment sale
order deliv third straight year top-lin gain compar
need come grow sale come
year despit high hurdl believ abbott pois grow organ
basi model call gradual slowdown year
assum modest deceler nutrit vs
establish pharma vs busi rel
consist perform diagnost vs alin continu roll
meanwhil expect cardiovascular neuro growth acceler vs
driven new product launch structur heart mitraclip portico amulet modest
recoveri neuromodul businesss recent struggl continu
momentum electrophysiolog heart failur
page analyst certif import disclosur
import element abbott growth acceler stori
past year wide margin libr expect global freestyl libr sale
come remark yoy level libr alon could
respons half abbott revenu growth report basi
nearli third organ gain extraordinari feat given compani size
strength busi figur show abbott organ revenu growth
ex-libr stay fairli consist past five year brief dip
grow contribut libr drive bulk compani
acceler bullish broader cgm market libr
growth potenti model sale expect growth
contribut fade next year pace cgm penetr gain slow
libr franchis matur
compani report guggenheim secur llc estim
compani report guggenheim secur llc estim
meanwhil see less opportun abbott drive leverag incom
statement go forward well compani grown earn
compound-annual-growth-rate driven strong top line momentum weve alreadi discuss
ebita margin expans back st jude deal synergi fall
interest expens manag delev ebitda post st jude aler
today reduct tax rate dont expect tax sourc
increment leverag bulk st jude cost synergi
harvest model call ebita leverag annual vs
abbott averag past three year leav balanc sheet
estim abbott could gener free cash flow
would still unspoken pay dividend compani also
debt come due period new ceo robert ford ampl
flexibl choos whether continu priorit de-lever buy back stock shift
toward aggress strategi abbott even quieter
front recent model assum cash deploy
combin debt paydown share buyback boost annual ep growth
next four year even financi leverag howev expect
abbott grow earn compound-annual-growth-rate level roughli in-lin
large-cap med-tech averag
page analyst certif import disclosur
top bottom-lin growth rate moder see abbott prime
candid multipl compress stock current trade
ep ebitda estim respect repres premium
large-cap med-tech averag roll sector multipl forward
assum abbott premium contract investor price slow
growth would impli stock price gain current level better
opportun elsewher coverag downgrad share buy
page analyst certif import disclosur
wake covidien merger emerg largest med-tech
compani world boast lead franchis across wide varieti end market
sinc compani work translat unmatch scale competit
advantag strategi yield mix result howev growth
recent year lag behind rest large-cap med-tech group expect
chang go forward pipeline-driven growth acceler narrow
perform gap peer visibl enhanc growth
outlook improv expect valuat gap rest large-cap
med-tech group close well drive meaning upsid current level
share current trade ntm ep estim
ntm ebitda repres discount large-cap med-tech group averag
respect pipelin kick next month see
medtron growth acceler top bottom line
respect roughli line broader group averag visibl improv
outlook increas expect stock trade less discount large-cap
med-tech peer upgrad share neutral buy establish
price target base multipl vs current
downsid risk rate includ clinic setback weaker-than-expect adopt
new product caus revenu fall short street estim better-than-expect
share gain competitor failur execut margin expans goal
page analyst certif import disclosur
abbott one largest healthcar compani world boast top line
lead franchis across medic devic diagnost nutrit establish
pharmaceut segment path get point long wind one
abbott reshuffl portfolio sever time past two decad recent
acquisit st jude medic aler deal help drive back-to-back
year top-lin gain low-teen earn growth benefit
acquisit mostli realiz howev see abbott growth
moder stori go forward perform gap abbott
large-cap med-tech peer set narrow go forward view see stock
fulli valu current level
abbott share current trade ntm ep estim ntm
ebitda large-cap med-tech averag respect
believ abbott above-averag growth profil peg
top bottom line respect vs group averag warrant
premium valuat see outlook fulli reflect stock current level
model call top- bottom-lin growth moder next
year believ stock risk multipl compress better opportun
elsewher within large-cap med-tech group opinion downgrad share
buy neutral
upsid risk rate includ continu out-performance broader med-tech
group drive multipl expans sector adopt key new product
libr alin portico etc exceed street expect prudent
account model caus revenu growth exceed expect
drive earn leverag excess model
downsid risk rate includ pipelin setback and/or neg clinic result
impact abbott competit adopt key new product libr alin
etc fall short street expect macro weak emerg market
countri abbott outsiz exposur rel mani peer
page analyst certif import disclosur
